Evaluation of OHIP-14 and OSHIP-14 in Patients With Varying Periodontal Disease (Cross-Section)

April 16, 2026 updated by: Esra ATEŞ, Abant Izzet Baysal University

Evaluation of OHIP-14 and OSHIP-14 in Patients With Varying Periodontal Disease Severity and Their Relationship With Clinical Findings: A Cross-Sectional Study

This study aims to evaluate periodontal health status and its impact on oral health-related quality of life by combining clinical periodontal parameters with validated patient-reported outcome measures. Periodontal assessments included probing pocket depth (PPD), clinical attachment loss (CAL), gingival index (GI), plaque index (PI), and bleeding on probing (BOP). Participants were further classified according to periodontal disease staging and grading. To assess the subjective impact of periodontal conditions on daily life, the Oral Health Impact Profile-14 (OHIP-14) and its shortened version, the Oral Health Impact Profile-14 short form (OShip-14), were administered.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

300

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey (Türkiye)
      • Bolu, Turkey (Türkiye), 14100
        • Bolu Abant İzzet Baysal Üniversity

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Systemically healthy individuals aged 18-65 years diagnosed with periodontitis and willing to participate in the study.

Description

Inclusion Criteria:

  • Aged between 18 and 65 years Diagnosed with periodontitis (any stage) Willing to participate in the study and provide informed consent

Exclusion Criteria:

  • Refusal to participate in the study Pregnancy or lactation Use of antibiotics or anti-inflammatory drugs within the last 3 months

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Stage I Periodontitis (Mild)
Participants with mild periodontitis characterized by initial periodontal breakdown, probing pocket depth (PPD) ≤4 mm, and minimal clinical attachment loss (CAL).
Other: No Interventions
Participants underwent a comprehensive periodontal examination, including probing pocket depth (PPD), clinical attachment loss (CAL), gingival index (GI), plaque index (PI), and bleeding on probing (BOP) assessments. In addition, oral health-related quality of life was evaluated using the OHIP-14 and OShip-14 questionnaires. No therapeutic or pharmacological intervention was applied.
Other Names:
  • Periodontal assessment and questionnaire evaluation
Stage II Periodontitis (Moderate)
Participants with moderate periodontitis characterized by PPD ≤5 mm and moderate CAL without significant functional impairment or tooth loss.
Other: No Interventions
Participants underwent a comprehensive periodontal examination, including probing pocket depth (PPD), clinical attachment loss (CAL), gingival index (GI), plaque index (PI), and bleeding on probing (BOP) assessments. In addition, oral health-related quality of life was evaluated using the OHIP-14 and OShip-14 questionnaires. No therapeutic or pharmacological intervention was applied.
Other Names:
  • Periodontal assessment and questionnaire evaluation
Group 3: Stage III Periodontitis (Severe)
Participants with severe periodontitis characterized by PPD ≥6 mm, advanced CAL, furcation involvement, and increased risk of tooth loss
Other: No Interventions
Participants underwent a comprehensive periodontal examination, including probing pocket depth (PPD), clinical attachment loss (CAL), gingival index (GI), plaque index (PI), and bleeding on probing (BOP) assessments. In addition, oral health-related quality of life was evaluated using the OHIP-14 and OShip-14 questionnaires. No therapeutic or pharmacological intervention was applied.
Other Names:
  • Periodontal assessment and questionnaire evaluation
Group 4: Stage IV Periodontitis (Advanced)
Participants with advanced periodontitis characterized by extensive attachment loss, severe bone destruction, and impaired masticatory function or tooth loss.
Other: No Interventions
Participants underwent a comprehensive periodontal examination, including probing pocket depth (PPD), clinical attachment loss (CAL), gingival index (GI), plaque index (PI), and bleeding on probing (BOP) assessments. In addition, oral health-related quality of life was evaluated using the OHIP-14 and OShip-14 questionnaires. No therapeutic or pharmacological intervention was applied.
Other Names:
  • Periodontal assessment and questionnaire evaluation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
OSHİP-14
Time Frame: One-time assessment at enrollment
OShip-14 is a 14-item short-form questionnaire designed to assess oral health-related quality of life, evaluating the physical, psychological, and social impacts of oral and dental health on daily life.
One-time assessment at enrollment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Abant Izzet Baysal University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2025

Primary Completion (Actual)

March 1, 2026

Study Completion (Estimated)

May 5, 2026

Study Registration Dates

First Submitted

April 16, 2026

First Submitted That Met QC Criteria

April 16, 2026

First Posted (Actual)

April 22, 2026

Study Record Updates

Last Update Posted (Actual)

April 22, 2026

Last Update Submitted That Met QC Criteria

April 16, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • BAIBÜ

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be shared to protect patient privacy and confidentiality.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Periodontal Disease

Clinical Trials on No Interventions

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe